Skip to content

#艾伯维

Today 0 items
Sep 30Wed
  1. biospace.com63

    AbbVie wins FDA approval for Parkinson’s drug from $8.7B Cerevel takeover

    The FDA has approved tavapadon, branded Juvmo, for adults with Parkinson's disease, giving AbbVie a marketed asset from its $8.7 billion Cerevel Therapeutics acquisition. BMO calls Juvmo the first selective D1/D5 receptor agonist available in the U.S., usable with or without levodopa. AbbVie will list it at $4,900 per 30-day supply, or $58,800 per year, and expects U.S. availability next month, targeting a market opportunity the company puts at $5 billion.

    Why it matters: Approval salvages a product from the Cerevel deal after emraclidine failed, and launches a first-in-class Parkinson's option.

Sep 27Sun
  1. endpoints.news40

    AbbVie's next-gen dopamine therapy for Parkinson's gets FDA approval

    The FDA has approved AbbVie's tavapadon, a next-generation therapy for Parkinson's disease designed to provide symptom relief comparable to its predecessors with fewer side effects. No further details on dosing, launch timing or pricing were available. The approval gives Parkinson's clinicians a new dopamine-based treatment option.

    Why it matters: FDA approval of a new Parkinson's drug is direct news for clinicians and industry readers.

Aug 29Sat
  1. biocentury.com48

    Mid-sized biotechs pressured to accept MFN deals crafted for big pharma

    A new round of most-favored nation drug pricing deals, expected to be announced as soon as Monday, reveals pressure from the Trump administration on mid-sized biopharmas. About 10 companies have accepted deals while others have resisted. The White House offers exemptions from mandatory Medicare MFN drug-pricing models and tariff relief in exchange for deep cuts to Medicaid reimbursement, with decisions hinging on payer mix and tariff exposure.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org